Previous 10 | Next 10 |
- Industry Leaders Will Learn How LinearDNA Can Significantly Improve RNA Manufacturing Speed, Simplicity, and Scalability in Comparison to Plasmid DNA - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today an...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced the formal launch of business development initiatives to expand the biotherapeutics industry’s awareness of the LinearDNA™ platform (the ...
- Positions CertainT® Platform as a Made in the USA Solution to Prove Non-Xinjiang Provenance or If Goods May Have Benefited from Forced Labor - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production,...
- Data Supports Initiation of First Canine Clinical Trial by Applied DNA to Advance Canine Lymphoma Cancer Vaccine Licensed from EvviVax - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its pr...
Applied DNA Sciences, Inc. (APDN) Q2 2022 Earnings Conference Call May 12, 2022, 04:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President & Chief Executive Officer Conference Call Participants Jonathan As...
Applied DNA Sciences press release (NASDAQ:APDN): Q1 GAAP EPS of -$0.23 beats by $0.10. Revenue of $6.15M (+130.3% Y/Y) beats by $1.65M. Cash at $6.5 Million Inclusive of Net Proceeds from Registered Direct Offering and Strong Cash Collections. Receives Request for Shipment of Traceable Tagge...
– Revenues at Record $6.1 Million, up 130% Year-over-Year and 48% Sequentially – – Cash at $6.5 Million Inclusive of Net Proceeds from Registered Direct Offering and Strong Cash Collections – – Receives Request for Shipment of Traceab...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The...
Applied DNA Sciences Inc. (NASDAQ:APDN) traded at a new 52-week high today of $20.00. Approximately 76.6 million shares have changed hands today, as compared to an average 30-day volume of 93,000 shares. There is potential upside of 8.5% for shares of Applied DNA Sciences Inc. based on a...
Applied DNA Sciences Inc. (NASDAQ:APDN) traded at a new 52-week high today of $20.00. This new high was reached on above average trading volume as 76.6 million shares traded hands, while the average 30-day volume is approximately 94,000 shares. Applied DNA Sciences Inc is a provider of D...
News, Short Squeeze, Breakout and More Instantly...
Applied DNA Sciences Inc. Company Name:
APDN Stock Symbol:
NASDAQ Market:
Applied DNA Sciences Inc. Website:
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCES...